Implantable Diabetes Treatment
Type 1 Diabetes
PreclinicalActive
Key Facts
About FluidForm Bio
FluidForm Bio is a private, preclinical-stage biotechnology company pioneering a novel 3D bioprinting platform called FRESH™. This platform uniquely prints cells and proteins in an aqueous environment to create complex, vascularized human tissues, with an initial focus on developing an implantable cure for Type 1 Diabetes. The company operates as a platform technology provider, partnering with life science firms while advancing its own lead program. Led by a team with deep expertise in medical technology and tissue engineering, FluidForm Bio aims to transform cell therapy by enabling long-term, minimally invasive implantable treatments.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |